Botulab

Botulab is a South Korean biotechnology company specializing in the development of next-generation botulinum toxin products for aesthetic and therapeutic use. Founded in 2020 by a team of experts with extensive experience in the toxin industry, the company focuses on producing high-purity botulinum toxin type A formulations. Their lead candidate, BL-101, is designed to offer improved safety and efficacy profiles compared to existing market alternatives. Botulab utilizes proprietary manufacturing and purification processes to minimize immunogenicity and enhance product stability. The company is currently advancing its pipeline through clinical trials in South Korea, targeting both the medical aesthetics and neurology markets.